Transvascular delivery of small interfering RNA to the central nervous system.

Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol (2011) 9.68

The promises and pitfalls of RNA-interference-based therapeutics. Nature (2009) 7.53

Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med (2008) 5.62

T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell (2008) 4.32

Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol (2009) 3.78

Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet (2008) 3.24

Endocytosis of nanomedicines. J Control Release (2010) 3.23

Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev (2010) 3.02

Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol (2009) 2.99

Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest (2007) 2.78

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76

Directing astroglia from the cerebral cortex into subtype specific functional neurons. PLoS Biol (2010) 2.60

Genome-wide detection and analysis of hippocampus core promoters using DeepCAGE. Genome Res (2008) 2.60

The emerging field of RNA nanotechnology. Nat Nanotechnol (2010) 2.45

Trafficking of immune cells in the central nervous system. J Clin Invest (2010) 2.17

A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity. J Exp Med (2011) 2.10

Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res (2008) 2.06

Mammalian cell penetration, siRNA transfection, and DNA transfection by supercharged proteins. Proc Natl Acad Sci U S A (2009) 1.95

An efficient Fmoc-SPPS approach for the generation of thioester peptide precursors for use in native chemical ligation. Angew Chem Int Ed Engl (2008) 1.95

Gold, poly(beta-amino ester) nanoparticles for small interfering RNA delivery. Nano Lett (2009) 1.86

Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev (2008) 1.83

Chemical modification: the key to clinical application of RNA interference? J Clin Invest (2007) 1.81

Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol Ther (2009) 1.76

A novel mechanism is involved in cationic lipid-mediated functional siRNA delivery. Mol Pharm (2009) 1.68

Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev (2009) 1.65

Progress toward in vivo use of siRNAs-II. Mol Ther (2011) 1.60

RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med (2009) 1.59

A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol Ther (2008) 1.58

Progress in microRNA delivery. J Control Release (2013) 1.58

RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther (2009) 1.55

Oligonucleotide therapeutic approaches for Huntington disease. J Clin Invest (2011) 1.54

Nonviral methods for siRNA delivery. Mol Pharm (2009) 1.50

Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. ACS Nano (2013) 1.47

microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain. J Neurosci (2015) 1.45

Transcriptome in vivo analysis (TIVA) of spatially defined single cells in live tissue. Nat Methods (2014) 1.44

Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv Mater (2012) 1.41

MicroRNAs in neurodegenerative diseases and their therapeutic potential. Pharmacol Ther (2011) 1.37

Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res (2011) 1.35

Allele-specific silencing of mutant Huntington's disease gene. J Neurochem (2009) 1.35

Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest (2007) 1.34

Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv Drug Deliv Rev (2007) 1.34

Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides. Bioconjug Chem (2011) 1.32

Image-guided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res (2010) 1.30

RNAi mechanisms and applications. Biotechniques (2008) 1.30

Vessel microport technique for applications in cerebrovascular research. J Neurosci Res (2009) 1.28

Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol Ther (2010) 1.28

Functional motor recovery from brain ischemic insult by carbon nanotube-mediated siRNA silencing. Proc Natl Acad Sci U S A (2011) 1.26

Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells. Mol Ther Nucleic Acids (2012) 1.24

Fifteen years of cell-penetrating, guanidinium-rich molecular transporters: basic science, research tools, and clinical applications. Acc Chem Res (2013) 1.20

Targeted delivery systems for oligonucleotide therapeutics. AAPS J (2009) 1.19

Aptamer-targeted cell-specific RNA interference. Silence (2010) 1.17

Regulation of haeme oxygenase-1 for treatment of neuroinflammation and brain disorders. Br J Pharmacol (2008) 1.14

Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery. Mol Ther (2012) 1.13

Extracellular caspase-6 drives murine inflammatory pain via microglial TNF-α secretion. J Clin Invest (2014) 1.12

Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J Extracell Vesicles (2015) 1.11

Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev (2011) 1.09

Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates. J Control Release (2011) 1.09

Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production. J Virol (2009) 1.06

Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res (2009) 1.06

Intracellular delivery of RNA-based therapeutics using aptamers. Ther Deliv (2010) 1.05

Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond) (2010) 1.05

Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo. Biomaterials (2014) 1.05

Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol Med (2009) 1.04

Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures. PLoS One (2010) 1.04

Genetic therapy for the nervous system. Hum Mol Genet (2011) 1.03

Understanding the dengue viruses and progress towards their control. Biomed Res Int (2013) 1.02

MITF-siRNA formulation is a safe and effective therapy for human melasma. Mol Ther (2010) 1.01

Acute 5-HT₁A autoreceptor knockdown increases antidepressant responses and serotonin release in stressful conditions. Psychopharmacology (Berl) (2012) 1.01

Targeted delivery of anti-coxsackievirus siRNAs using ligand-conjugated packaging RNAs. Antiviral Res (2009) 1.01

The Business of RNAi Therapeutics in 2012. Mol Ther Nucleic Acids (2012) 1.01

An epididymis-specific secretory protein HongrES1 critically regulates sperm capacitation and male fertility. PLoS One (2008) 1.01

RNAi medicine for the brain: progresses and challenges. Hum Mol Genet (2011) 1.00

Concepts in in vivo siRNA delivery for cancer therapy. J Cell Physiol (2009) 0.98

B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv Immunol (2008) 0.98

microRNAs: tiny regulators of synapse function in development and disease. J Cell Mol Med (2008) 0.98

A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells. BMC Cancer (2011) 0.97

Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression. J Biol Chem (2008) 0.96

MicroRNAs and cancer therapy: the next wave or here to stay? Cancer Biol Ther (2010) 0.95

Molecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infections. Proc Natl Acad Sci U S A (2012) 0.95

Antiviral RNAi: translating science towards therapeutic success. Pharm Res (2011) 0.94

Human macrophage and dendritic cell-specific silencing of high-mobility group protein B1 ameliorates sepsis in a humanized mouse model. Proc Natl Acad Sci U S A (2012) 0.94

Tumor-targeted Chlorotoxin-coupled Nanoparticles for Nucleic Acid Delivery to Glioblastoma Cells: A Promising System for Glioblastoma Treatment. Mol Ther Nucleic Acids (2013) 0.94

Efficient delivery of RNA Interference to peripheral neurons in vivo using herpes simplex virus. Nucleic Acids Res (2008) 0.93

Brain-specific knockdown of miR-29 results in neuronal cell death and ataxia in mice. RNA (2014) 0.93

Pharmacological treatment for heart failure: a view from the brain. Clin Pharmacol Ther (2009) 0.93

The therapeutic potential of microRNAs in nervous system damage, degeneration, and repair. Neuromolecular Med (2009) 0.92

Recent developments in peptide-based nucleic acid delivery. Int J Mol Sci (2008) 0.92

Degradation of nuclease-stabilized RNA oligonucleotides in Mycoplasma-contaminated cell culture media. Nucleic Acid Ther (2012) 0.92

Hydrophobically Modified siRNAs Silence Huntingtin mRNA in Primary Neurons and Mouse Brain. Mol Ther Nucleic Acids (2015) 0.91

Cyclin D1 induction of Dicer governs microRNA processing and expression in breast cancer. Nat Commun (2013) 0.91

Activation of the Nrf2-ARE pathway by siRNA knockdown of Keap1 reduces oxidative stress and provides partial protection from MPTP-mediated neurotoxicity. Neurotoxicology (2012) 0.91

Progress toward therapy with antisense-mediated splicing modulation. Curr Opin Mol Ther (2009) 0.91

Lentiviral delivery of RNAi for in vivo lineage-specific modulation of gene expression in mouse lung macrophages. Mol Ther (2013) 0.91

Peptide-mediated cellular delivery of oligonucleotide-based therapeutics in vitro: quantitative evaluation of overall efficacy employing easy to handle reporter systems. Curr Pharm Des (2008) 0.91

Progress on RNAi-based molecular medicines. Int J Nanomedicine (2012) 0.90

Silencing IL-13Rα2 promotes glioblastoma cell death via endogenous signaling. Mol Cancer Ther (2011) 0.90

Dendrimer advances for the central nervous system delivery of therapeutics. ACS Chem Neurosci (2013) 0.90

High-density lipoprotein facilitates in vivo delivery of α-tocopherol-conjugated short-interfering RNA to the brain. Hum Gene Ther (2011) 0.90

Silencing early viral replication in macrophages and dendritic cells effectively suppresses flavivirus encephalitis. PLoS One (2011) 0.89

Nanostructures: a platform for brain repair and augmentation. Front Syst Neurosci (2014) 0.89

Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature (2003) 7.56

RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med (2003) 7.37

RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol (2006) 6.81

Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40

siRNA-directed inhibition of HIV-1 infection. Nat Med (2002) 6.36

siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol (2002) 5.65

miRNA profiling of naïve, effector and memory CD8 T cells. PLoS One (2007) 5.43

RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A (2005) 4.79

RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med (2004) 4.63

Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A (2008) 4.53

T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell (2008) 4.32

Migratory properties of naive, effector, and memory CD8(+) T cells. J Exp Med (2001) 4.17

The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease. J Neurosci (2008) 3.62

Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A (2003) 3.00

Rapid diagnosis of tuberculous meningitis by polymerase chain reaction. Lancet (1991) 2.77

Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther (2008) 2.66

Structure and activity of putative intronic miRNA promoters. RNA (2010) 2.50

Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther (2009) 2.47

Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med (2003) 2.43

Identification of Mycobacterium tuberculosis by polymerase chain reaction. Lancet (1990) 2.39

Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol (2003) 2.26

MicroRNAs potentiate neural development. Neuron (2009) 2.25

Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood (2001) 2.13

CD70+ antigen-presenting cells control the proliferation and differentiation of T cells in the intestinal mucosa. Nat Immunol (2005) 2.02

Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood (2002) 1.94

Restoring Acid-sensing ion channel-1a in the amygdala of knock-out mice rescues fear memory but not unconditioned fear responses. J Neurosci (2008) 1.90

Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity (2003) 1.84

Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol Ther (2008) 1.82

Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size. J Virol (2002) 1.77

Targeted viral delivery of Cre recombinase induces conditional gene deletion in cardiovascular circuits of the mouse brain. Physiol Genomics (2004) 1.74

CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection. Blood (2001) 1.74

Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med (2009) 1.72

Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol Ther (2011) 1.72

Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA (2008) 1.70

Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev (2009) 1.65

Alternative processing of primary microRNA transcripts by Drosha generates 5' end variation of mature microRNA. PLoS One (2009) 1.63

Clarifying lysosomal storage diseases. Trends Neurosci (2011) 1.57

CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J Neurosci (2005) 1.57

Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat Med (2009) 1.57

Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J Neurosci (2005) 1.56

A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration. J Neurosci (2004) 1.56

A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PLoS Med (2006) 1.55

RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther (2009) 1.55

Gene therapy for lysosomal storage diseases. Mol Ther (2006) 1.55

Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum Gene Ther (2009) 1.55

Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. Blood (2005) 1.54

Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia. J Neurosci (2005) 1.53

Diverse splicing patterns of exonized Alu elements in human tissues. PLoS Genet (2008) 1.52

Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease. Hum Mol Genet (2011) 1.48

Lentivirus vectors pseudotyped with filoviral envelope glycoproteins transduce airway epithelia from the apical surface independently of folate receptor alpha. J Virol (2003) 1.45

Dynamic regulation of T cell immunity by CD43. J Immunol (2002) 1.45

Adenosine deamination in human transcripts generates novel microRNA binding sites. Hum Mol Genet (2009) 1.43

Migration and differentiation of CD8+ T cells. Immunol Rev (2002) 1.41

Widespread establishment and regulatory impact of Alu exons in human genes. Proc Natl Acad Sci U S A (2011) 1.40

TCR signaling induces selective exclusion of CD43 from the T cell-antigen-presenting cell contact site. J Immunol (1998) 1.37

Negative regulation of T cell homing by CD43. Immunity (1998) 1.36

Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc Natl Acad Sci U S A (2002) 1.33

Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. J Neurosci (2006) 1.33

Connecdenn, a novel DENN domain-containing protein of neuronal clathrin-coated vesicles functioning in synaptic vesicle endocytosis. J Neurosci (2006) 1.33

Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol Ther (2010) 1.28

Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Res (2004) 1.27

Selective gene transfer to key cardiovascular regions of the brain: comparison of two viral vector systems. Hypertension (2002) 1.27

The prospect of silencing disease using RNA interference. JAMA (2005) 1.24

The transcription factor ATF4 promotes skeletal myofiber atrophy during fasting. Mol Endocrinol (2010) 1.23

Integration site choice of a feline immunodeficiency virus vector. J Virol (2006) 1.20

Rho GTPases modulate entry of Ebola virus and vesicular stomatitis virus pseudotyped vectors. J Virol (2009) 1.20

In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins. J Virol (2002) 1.16

Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer. Blood (2005) 1.14

Cutting Edge: Distinct NK receptor profiles are imprinted on CD8 T cells in the mucosa and periphery during the same antigen challenge: role of tissue-specific factors. J Immunol (2007) 1.12

Adeno-associated virus type 5: transduction efficiency and cell-type specificity in the primate retina. Hum Gene Ther (2003) 1.12

Lower and upper stem-single-stranded RNA junctions together determine the Drosha cleavage site. Proc Natl Acad Sci U S A (2013) 1.12

Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease. Mol Ther (2007) 1.11

Defining the pathway for Tat-mediated delivery of beta-glucuronidase in cultured cells and MPS VII mice. Mol Ther (2005) 1.10

Interfering with disease: opportunities and roadblocks to harnessing RNA interference. Trends Mol Med (2003) 1.10

Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. Mol Ther (2011) 1.09

Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease. Mol Ther (2009) 1.09

The functional CD8 T cell response to HIV becomes type-specific in progressive disease. J Clin Invest (2002) 1.09

Newer gene editing technologies toward HIV gene therapy. Viruses (2013) 1.07

Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production. J Virol (2009) 1.06

Impaired immune response to vaccinia virus inoculated at the site of cutaneous allergic inflammation. J Allergy Clin Immunol (2007) 1.05

Huntington's disease: progress toward effective disease-modifying treatments and a cure. Hum Mol Genet (2010) 1.05

A macrophage invasion mechanism for mycobacteria implicating the extracellular domain of CD43. J Exp Med (2000) 1.05

Membrane topology of CLN3, the protein underlying Batten disease. FEBS Lett (2003) 1.04

Gene transfer to the nonhuman primate retina with recombinant feline immunodeficiency virus vectors. Hum Gene Ther (2002) 1.04

Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol Med (2009) 1.04

Interfering antiviral immunity: application, subversion, hope? Trends Immunol (2006) 1.03